Patent 11359015 was granted and assigned to Genmab A/S on June, 2022 by the United States Patent and Trademark Office.
The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.